ACK1缺失上调EGFR并介导BRAF抑制剂耐药
该研究探讨黑色素瘤对BRAF抑制剂耐药的机制,发现ACK1在维莫非尼耐药细胞中下调,ACK1敲低可减少EGFR降解、增加EGFR蛋白表达,并在体外和体内赋予BRAF抑制剂耐药,该耐药可被EGFR抑制剂吉非替尼逆转。
要点
- ACK1在维莫非尼耐药黑色素瘤细胞中下调。
- ACK1敲低减少EGFR降解并增加EGFR蛋白表达。
- ACK1缺失介导的耐药可被吉非替尼逆转。
核心结论
- ACK1缺失可能通过转录后机制增加EGFR信号并贡献于BRAF抑制剂耐药。
研究设计与样本
- 研究在维莫非尼耐药黑色素瘤细胞中检测ACK1表达,并用shRNA敲低ACK1进行体外和体内实验。
主要发现
- ACK1在维莫非尼耐药黑色素瘤细胞中下调。
- shRNA敲低ACK1减少EGF激活后的EGFR降解并增加EGFR蛋白表达。
- ACK1敲低在体外和体内赋予BRAF抑制剂耐药。
- ACK1抑制介导的维莫非尼耐药可被EGFR抑制剂吉非替尼逆转。
关键数值与推荐
- ACK1敲低减少EGFR降解、增加EGFR蛋白表达,并 confer 对BRAF抑制剂的耐药。
- 吉非替尼可逆转ACK1抑制介导的维莫非尼耐药。
临床怎么用
- EGFR抑制剂吉非替尼可能用于逆转ACK1缺失介导的BRAF抑制剂耐药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Targeted BRAF(V600E) suppression by selective BRAF inhibitors (BRAFis; e.g., vemurafenib and dabrafenib) has led to a sea change in the treatment of metastatic melanoma. Despite frequent upfront responses, acquired resistance has compromised long-term applicability. Among the various mechanisms of resistance, activation of multiple receptor tyrosine kinases is a known critical factor that contributes to vemurafenib resistance. EGFR activation has been recurrently identified in a set of vemurafenib-resistant melanomas, but little is known about how EGFR, or possibly other receptor tyrosine kinases, becomes activated. Here, we report that ACK1, a protein kinase that modulates EGFR turnover, is downregulated in vemurafenib-resistant melanoma cells. We also found that ACK1 depletion with short hairpin RNA decreased EGFR degradation when activated by epidermal growth factor, increased EGFR protein expression, and conferred resistance to BRAFis both in vitro and in vivo. Vemurafenib resistance mediated by ACK1 inhibition can be reversed by the EGFR inhibitor gefitinib. Our data indicate that ACK1 loss may be a post-transcriptional mechanism that increases EGFR signaling and contributes to drug resistance.
引用
- Ji Z, Njauw CN, Guhan S, et al. Loss of ACK1 Upregulates EGFR and Mediates Resistance to BRAF Inhibition. J Invest Dermatol. 2020. PMID: 33159968. doi:10.1016/j.jid.2020.06.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。